Literature DB >> 18832247

Hepatitis B virus infection.

Jules L Dienstag1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18832247     DOI： 10.1056/NEJMra0801644

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  297 in total

Review 1.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

2.  Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine.

Authors:  Shih-Hung Tsai; Ming-Shen Dai; Jyh-Cherng Yu; Ching-Liang Ho; Yeu-Chin Chen; Yi-Ying Wu; Ping-Ying Chang; Woei-Yau Kao; Tsu-Yi Chao
Journal:  Support Care Cancer       Date:  2010-10-07       Impact factor: 3.603

Review 3.  Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

4.  Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease.

Authors:  Christopher P Desmond; Silvana Gaudieri; Ian R James; Katja Pfafferott; Abha Chopra; George K Lau; Jennifer Audsley; Caroline Day; Sarah Chivers; Adam Gordon; Peter A Revill; Scott Bowden; Anna Ayres; Paul V Desmond; Alexander J Thompson; Stuart K Roberts; Stephen A Locarnini; Simon A Mallal; Sharon R Lewin
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 5.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

6.  Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.

Authors:  Jorge Méndez-Navarro; Kathleen E Corey; Hui Zheng; Lydia L Barlow; Jae Young Jang; Wenyu Lin; Hong Zhao; Run-Xuan Shao; Steven L McAfee; Raymond T Chung
Journal:  Liver Int       Date:  2010-08-25       Impact factor: 5.828

Review 7.  When treating cancer, please don't forget hepatitis B.

Authors:  Lindsay Y King; Raymond T Chung
Journal:  Oncologist       Date:  2010-07-20

8.  Reactivation of hepatitis B: pathogenesis and clinical implications.

Authors:  Anthony Post; Shweta Nagendra
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

Review 9.  Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.

Authors:  María Buti; Itziar Oyagüez; Virginia Lozano; Miguel A Casado
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 10.  Hepatitis B vaccination.

Authors:  Luisa Romanò; Sara Paladini; Cristina Galli; Giovanni Raimondo; Teresa Pollicino; Alessandro R Zanetti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.